| imported malaria in australia. | to obtain information on imported malaria in australia. | 1991 | 1745165 |
| communicable diseases network australia: national arbovirus and malaria advisory committee annual report 2004-05. | this report describes the epidemiology of mosquito-borne disease in australia for the mosquito-borne disease season 1 july 2004 to 30 june 2005. ross river virus (rrv) infections (45%), barmah forest virus (bfv) infections (30%) and malaria (19%) were the most common mosquito-borne diseases reported in 2004-05. the northern territory had the highest rate of rrv notifications and the peak notification rate (in february 2005) was 54 per cent less than the previous season. the northern territory al ... | 2005 | 16465923 |
| communicable diseases network australia national arbovirus and malaria advisory committee annual report, 2005-06. | this report describes the epidemiology of mosquito-borne disease in australia for the mosquito-borne disease season 1 july 2005 to 30 june 2006, in which the second largest number of notifications since 1995-96 was reported. ross river virus (rrv) infections (66%), barmah forest virus (bfv) infections (23%) and malaria (9%) were the most common mosquito-borne diseases reported in 2005-06. national rrv notifications were the fifth largest on record. the northern territory had the highest rate of ... | 2006 | 17330382 |
| communicable diseases network australia national arbovirus and malaria advisory committee annual report, 2006-07. | this report describes the epidemiology of mosquito-borne disease in australia for the mosquito-borne disease season 1 july 2006 to 30 june 2007, which was moderately low compared to previous seasons. ross river virus (rrv) infections (55%), barmah forest virus (bfv) infections (29%) and overseas acquired malaria (11%) were the most common mosquito-borne diseases reported in 2006-07. the number, proportion and rate of national bfv notifications were the second highest on record since 1998-99. the ... | 2008 | 18522303 |
| the efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of plasmodium vivax malaria in the southwest pacific. | tafenoquine is being developed for radical cure and post-exposure prophylaxis of plasmodium vivax malaria. in an open-label study, 1512 australian defence force personnel received one of three tafenoquine 3 d regimens [400 mg once daily (od), 200 mg twice daily (bid), 200 mg od] or daily primaquine (22.5 mg) plus doxycycline (100 mg) over 14 d in bougainville and in timor-leste for post-exposure prophylaxis. the relapse rate of subjects treated in bougainville with tafenoquine (n=173) was 1.2% ( ... | 2008 | 18541280 |
| randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects. | this study represents the first phase iii trial of the safety, tolerability, and effectiveness of tafenoquine for malaria prophylaxis. in a randomized (3:1), double-blinded study, australian soldiers received weekly malaria prophylaxis with 200 mg tafenoquine (492 subjects) or 250 mg mefloquine (162 subjects) for 6 months on a peacekeeping deployment to east timor. after returning to australia, tafenoquine-receiving subjects received a placebo and mefloquine-receiving subjects received 30 mg pri ... | 2010 | 19995933 |